AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02093026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants will receive methotrexate 10-25 mg/week orally or parenterally.
Study NCT05527639 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: strength training program
Description: 12-weeks of strength training consisting of warm ups, dead-lifts, squats and cool down exercises
Study NCT02093026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Participants will receive methylprednisolone 100 mg IV 30 minutes prior to each rituximab infusion.
Study NCT00063999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00063999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT00063999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT03940170 — intervention group
Intervention type: DEVICE
Intervention: vistacam proof
Description: Light fluorescence device
Study NCT03940170 — intervention group
Intervention type: OTHER
Intervention: ICDASII
Description: visual examination
Study NCT03940170 — intervention group
Intervention type: PROCEDURE
Intervention: fissurotomy
Description: histological validation
Study NCT00063999 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Given SC
Study NCT00063999 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00063999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02021461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESL Banana taste
Description: oral suspension with Banana flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
Study NCT02021461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESL Grape taste
Description: oral suspension with Grape flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
Study NCT00063999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT00063999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02093026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Participants will receive folic acid >= 5 mg/week or equivalent.
Study NCT00063999 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: Given SC
Study NCT04281953 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: High frequency audiometry
Description: Simple hearing test
Study NCT04281953 — intervention group
Intervention type: OTHER
Intervention: Short-Form 36-Item Questionnaire (SF-36)
Description: Questionnaire on quality of life (Short Form 36 Item- SF-36)
Study NCT04281953 — intervention group
Intervention type: OTHER
Intervention: Hearing handicap inventory for adults/elderly (HHIA/HHIE)
Description: Questionnaire on Hearing loss (Hearing handicap inventory for adults/elderly- HHIA/HHIE)
Study NCT04281953 — intervention group
Intervention type: OTHER
Intervention: Tinnitus handicap inventory (THI)
Description: Questionnaire on Tinnitus (Tinnitus Handicap Inventory)
Study NCT02021461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESL Tutti-Frutti taste
Description: oral suspension with Tutti-Frutti flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
Study NCT02067312 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Thai massage
Study NCT01112683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: The drug dosage will follow memantine's standard titration schedule (i.e., 5 mg/d week one, 5 mg/BID week two, 5 \& 10 mg/d divided dose week three, 10mg/BID week four).
Study NCT01112683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: These are identically-looking pills to those in the Memantine Arm.
Study NCT01686802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral morphine
Study NCT01686802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study NCT03363425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Iv
Description: Lidocaine Iv
Study NCT03363425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine iv
Study NCT03363425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: placebo
Study NCT01732653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TT+VR
Description: subjects will be walking on a treadmill while negotiating virtual obstacles provided by a computer simulation. The virtual environment will consist of obstacles, different pathways, narrow corridors and distracters, requiring modulations of step amplitude in two planes (i.e., height and width) coordinated with walking behaviour. The speed, orientation, size, frequency of appearance and shape of the targets will be manipulated according to individual needs following a standardized protocol.
Study NCT01732653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TT alone
Description: The participants will walk on the treadmill, their gait speed over-ground will be measured at the beginning of each week of training. Progression will include increasing the duration of each of the walking bouts and increasing walking speed.
Study NCT01620359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate MRgFUS
Description: 100% ablation of an up-to-2-cm breast cancer visible on an contrast-enhanced MRI with 5-10 mm margins around the primary tumor
Study NCT02067312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thai massage
Study NCT04537637 — intervention group
Intervention type: DRUG
Intervention: Oral Semaglutide
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Study NCT01031095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: coronary intervention
Description: elective coronary intervention
Study NCT01031095 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: coronary intervention
Description: elective coronary intervention
Study NCT00797342 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PF-04629991
Description: Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the first cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
Study NCT00797342 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PF-04629991
Description: Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the second cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
Study NCT00077233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: IV
Study NCT00077233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: IV
Study NCT00077233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: IV
Study NCT00077233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: IV
Study NCT00077233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: IV
Study NCT00077233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin
Description: IV
Study NCT00077233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: IV
Study NCT00797342 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PF-04629991
Description: Oral; sequential single dose escalation; three fourteen-day treatment periods per subject in the third cohort; randomized assignment to treatment (placebo or PF-04629991)
Study NCT04264052 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CBE & MRI
Description: The diagnostic tests will be consisted by two visits.~In the first visit participants will undergo a medical history assessment and they will complete questionnaires related to the lung function (MRC Dyspnoea score, Dyspnoea-12 questionnaire, and Visual Analogue Scale). A spirometry will be performed to assess the lung function. Bronchoscopy will be performed at rest in a semi-supine position (on a reclined bed) and then during exercise on a treadmill.~In the second visit, spirometry and questionnaires will be performed prior to resting and during exercise measurements on a magnetic resonance imaging (MRI) scan.~Rest: Structural imaging of the neck and chest will be performed followed by dynamic imaging of the airways during several inspiratory and expiratory manoeuvres. No IV contrast media will be used.
Study NCT01649843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POEM
Description: Peroral endoscopic myotomy (POEM) has recently been described as a new minimally invasive endoscopic myotomy technique intending a permanent cure from primary achalasia in some centers.
Study NCT02270437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine, fentanyl, adrenaline
Description: The patients in the cocktail analgesia group received an injection of 200mg ropivacaine, 100ug fentanyl, and 0.25mg adrenaline into knee collateral ligaments, posterior aspect of the capsule, quadriceps tendon, patellar tendon, fat pad, periosteum, and synovium, along with PCIA morphine postoperatively.
Study NCT01967784 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine (split virion, inactivated)
Description: 0.5 mL, Intramuscular
Study NCT02895009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: experimental group
Description: Participants allocated to the experimental group will receive a short term postoperative puncture site compression via TR Band. TR Band deflation is commenced at the 1st hour and completed at the 3rd hour, and the TR Band is removed at the 12th hour.
Study NCT02895009 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: control group
Description: Participants allocated to the control group will receive a routine long term postoperative puncture site compression via TR Band. TR Band deflation is commenced at the 2nd hour and completed at the 6th hour, and the TR Band is removed at the 24th hour.
Study NCT04033523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: The HF group performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 3 days/week for 12 weeks
Study NCT01009281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Study NCT00876798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixivaptan
Description: Capsules, 25mg lixivaptan or matching placebo once daily. Study medication can be titrated up to 50mg or 100mg once daily. Acceptable dosages are once daily administration of 25mg, 50mg, or 100mg as a single dose.
Study NCT00876798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule. Subjects will be randomized (3:1) on an outpatient basis to 25 mg lixivaptan or matching placebo, once daily.
Study NCT01650675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WIDUS computer-delivered, indirect brief intervention
Description: A single 20-minute interactive computer-delivered intervention designed to promote motivation to change drug use and risky sexual behavior, if any, without presuming those risks to be specifically present.
Study NCT01650675 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition time control/placebo intervention
Description: This time-control intervention, designed in part to help promote RA blinding as to participant condition, focuses on proper infant nutrition using a computer-delivered, interactive format and videos.
Study NCT03914300 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03914300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT01685346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: biofeedback-mediated stress management (BFSM)
Description: Therapist and study assistant meet with patient, attach sensors, record physiologic variables and train the patient in relaxation techniques including deep breathing, guided imagery, progressive muscle relaxation, autogenics. Patient is given a handheld thermometer to take home and practice self-regulation between visits, along with a recording sheet to indicate how often practice occurs.
Study NCT03348787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral and Cognitive Therapies
Description: Group intervention of 6 weekly sessions of one hour and 30 minutes based on the psychoeducational therapeutic principles and CBT type 3 wave Accept Voices applied to HAV
Study NCT04738929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extra virgin coconut oil or extra virgin olive oil
Description: Subjects consumed standard breakfast meals containing extra virgin coconut oil or extra virgin olive oil
Study NCT01299701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA404
Description: (5,6-dimethylxanthenone-4-acetic acid) DMXAA or DXAA
Study NCT00476047 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tositumomab and Iodine I 131 Tositumomab
Description: Give IV
Study NCT02203084 — intervention group
Intervention type: OTHER
Intervention: Social Determinants Questionnaire
Description: The questionnaire contains a general background information section common to all medical conditions. It then contains separate sections with medical condition specific questions.
Study NCT01056380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Tablet, 500 mg with food twice daily for 5 days
Study NCT01056380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, twice daily with food for 5 days
Study NCT00644644 — intervention group
Intervention type: OTHER
Intervention: Rapid Response Team (NTX wireless monitoring system)
Description: If the subject is experiencing a life threatening change in their vital signs, the Rapid Response Team will be initiated per VUMC protocol.
Study NCT00077233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: IV
Study NCT00077233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: IV
Study NCT00731029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thiomersal free trivalent influenza split vaccine 2002/2003
Description: Single dose, intramuscular injection
Study NCT00731029 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2002/2003
Description: Single dose, intramuscular injection
Study NCT00847717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective neck dissection
Description: Level IIb preserving neck dissection
Study NCT00847717 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional Neck dissection
Description: Conventional neck dissection (MRND type III or Supraomohyoid)
Study NCT02641899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650 20/60 mcg/day
Description: ITCA 650 osmotic mini pump delivering exenatide 20 mcg/day for 14 days, followed by ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day.
Study NCT02641899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Oral acetaminophen 1000 mg on Day 1 and Day 27
Study NCT02054871 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC
Description: A standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 3 ischaemia-reperfusion cycles. Additional, blood and urine samples will be collected on Day 1, Day 2 and Day 3 post procedure.
Study NCT01733927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid testing for HIV
Description: The research team members were trained and certified in administering the OQA testing through the AIDS International Consortium in Philadelphia (WHCI), USA. During the recruitment process, participants were informed about the nature of the test, the length of time for results, and what procedures would be involved in self-administering the OQA test. After providing informed consent, including the release of information for research use, participants demonstrated their ability to properly take an OQA sample using a popsicle stick as a proxy for the testing device.
Study NCT04080687 — intervention group
Intervention type: DEVICE
Intervention: Ankle-foot orthosis
Description: Ankle-foot orthosis of any type (unilateral or bilateral, standard or carbon fiber, for support or correction)
Study NCT00739492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: financial incentives
Description: financial incentives based on attaining weight loss goals
Study NCT01673750 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: The primary outcome, characterizing body image among HIV infected adolescents, will be measured using a questionnaire administered to study participants through Audio Computer Assisted Self-Interview (ACASI) technology.
Study NCT01302015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RNL-Vascostem®
Study NCT03914300 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT02891005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: paclitaxel controlled release balloon catheter (VasoguardTM)
Description: paclitaxel controlled release balloon catheter implantation for small vessel lesion
Study NCT02891005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: common balloon catheter (Maverick2)
Description: common balloon catheter implantation for small vessel lesion
Study NCT03924531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Awareness Program
Description: 2-hour mindfulness training for 6 weeks.
Study NCT03924531 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion Program
Description: Health Promotion Program
Study NCT02029599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fang yi qing feng shi granule
Description: 10g, Oral,Three each time, 3 times a day,for 3 months;
Study NCT02029599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: 10g, Oral,Three each time, 3 times a day,for 3 months
Study NCT02029599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 10g, Oral,Three each time, 3 times a day,for 3 months
Study NCT02029599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 7.5-15mg per week，All patients should be used
Study NCT02029599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: 7.5-15mg per week，All patients should be used
Study NCT02029599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen tablets
Description: Oral,0.5g, 1\~2 times a day, when vas=10
Study NCT02029599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen tablets
Description: Oral,0.5g, 1\~2 times a day, when vas=10
Study NCT00246688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (BAY86-5302 , ZK219477)
Description: 10.5 mg lyophilized sagopilone per vial
Study NCT00848003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium animalis subsp. lactis strain BB-12
Description: Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days
Study NCT00848003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Strawberry flavored yogurt
Study NCT01593722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diethylcarbamazine
Description: single dose
Study NCT01593722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: single dose
Study NCT00434343 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Global Therapeutic Massage (GTM)
Study NCT02641899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Oral atorvastatin 40 mg on Day 2 and Day 28
Study NCT02641899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Oral lisinopril 20 mg on Day 2 and Day 28
Study NCT02641899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Oral warfarin 25 mg on Day 2 and Day 28